Evidence map›Paper›PMID 40537712›Full record

ArticleMolecular diversity2026

Development of a novel multi-epitope vaccine against Ureaplasma urealyticum infection through reverse vaccinology approach.

Linglan Xu, Nan Xie, Yiqin Liu, Hongmei Tang, Jinjiang He, Zhen He, Kang Zheng, Ranhui Li

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Linglan XuHunan Province Clinical Medical Research Center for Occupational Diseases, Hunan Prevention and Treatment Institute for Occupational Diseases, Affiliated Prevention and Treatment Institute for Occupational Diseases of University of South China, University of South China, Changsha, 410007, China.
Nan XieInstitute of Pathogenic Biology, School of Basic Medicine, Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control, Hengyang Medical College, University of South China, Hengyang, Hunan, China.
Yiqin LiuInstitute of Pathogenic Biology, School of Basic Medicine, Hunan Provincial Key Laboratory for Special Pathogens Prevention and Control, Hengyang Medical College, University of South China, Hengyang, Hunan, China.
Hongmei TangHunan Province Clinical Medical Research Center for Occupational Diseases, Hunan Prevention and Treatment Institute for Occupational Diseases, Affiliated Prevention and Treatment Institute for Occupational Diseases of University of South China, University of South China, Changsha, 410007, China.
Jinjiang HeHunan Province Clinical Medical Research Center for Occupational Diseases, Hunan Prevention and Treatment Institute for Occupational Diseases, Affiliated Prevention and Treatment Institute for Occupational Diseases of University of South China, University of South China, Changsha, 410007, China.
Zhen HeHunan Province Clinical Medical Research Center for Occupational Diseases, Hunan Prevention and Treatment Institute for Occupational Diseases, Affiliated Prevention and Treatment Institute for Occupational Diseases of University of South China, University of South China, Changsha, 410007, China.
Kang ZhengAffiliated Hengyang Hospital of Hunan Normal University & Hengyang Central Hospital, Hengyang, 421001, Hunan, China. zhengkang1221@sina.com.
Ranhui LiHunan Province Clinical Medical Research Center for Occupational Diseases, Hunan Prevention and Treatment Institute for Occupational Diseases, Affiliated Prevention and Treatment Institute for Occupational Diseases of University of South China, University of South China, Changsha, 410007, China. liranhui@usc.edu.cn.

Funding

Natural Science Foundation of Hunan Province 2023JJ30523
6 · The paper itself

Abstract

Ureaplasma urealyticum (U. urealyticum) is a sexually transmitted pathogen often causing urogenital tract disorders. The growing challenge of multidrug-resistant strains poses a significant risk for the treatment of U. urealyticum infections. To date, no licensed vaccines are available, and previous attempts to create secure and efficient prophylaxis have been failed. Recent studies have adopted an immunoinformatic strategy based on reverse vaccinology to detect antigenic proteins which are appropriate for the creation of a multi-epitope vaccine. The multi-epitope subunit vaccine, incorporating eleven T-cell and seven B-cell epitopes along with the adjuvant, exhibited strong antigenicity and did not induce allergic responses. Moreover, molecular docking as well as dynamic simulations were utilized to investigate the interaction within the vaccine-adjuvant complex. The prospective effectiveness of the vaccine was verified via immune simulation experiments. Therefore, the vaccine developed in this study represents an effective multi-epitope solution for immunization against U. urealyticum, waiting for further experimental analysis.

Indexed as

Bacterial VaccinesEpitopes, B-LymphocyteEpitopes, T-LymphocyteUreaplasma InfectionsUreaplasma urealyticumAnimalsHumansMiceMolecular Docking SimulationVaccine DevelopmentVaccines, SubunitVaccinologyBacterial VaccinesEpitopes, B-LymphocyteEpitopes, T-LymphocyteVaccines, SubunitImmune simulationImmunoinformaticMolecular dockingMolecular dynamics simulationReverse vaccinologySubtractive proteomicsUreaplasma urealyticum

Identifiers

PMID40537712

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.